Prime Medicine, Inc. Contracts & Agreements
32 Contracts & Agreements
- Business Finance (7 contracts)
- Business Operations (3)
- Human Resources (13)
- Intellectual Property (8)
- Uncategorized (1)
- Amendment No. 1 to the Amended and Restated Employment Agreement, dated (Filed With SEC on November 3, 2023)
- Sixth Amendment to License Agreement, dated April 5, 2022, between Prime Medicine, Inc. and MIL 21E, LLC (Filed With SEC on August 7, 2023)
- Ninth Amendment to License Agreement, dated March 17, 2023, between Prime Medicine, Inc. and MIL 21E, LLC (Filed With SEC on August 7, 2023)
- Tenth Amendment to License Agreement, dated April 14, 2023, between Prime Medicine, Inc. and MIL 21E, LLC (Filed With SEC on August 7, 2023)
- Eleventh Amendment to License Agreement, dated May 4, 2023, between Prime Medicine, Inc. and MIL 21E, LLC (Filed With SEC on August 7, 2023)
- 2019 Stock Option and Grant Plan, as amended, and forms of award agreements thereunder (Filed With SEC on October 13, 2022)
- 2022 Stock Option and Incentive Plan and forms of award agreements thereunder (Filed With SEC on October 13, 2022)
- 2022 Employee Stock Purchase Plan (Filed With SEC on October 13, 2022)
- Form of Executive Employment Agreement (Filed With SEC on October 13, 2022)
- Form of Underwriting Agreement (Filed With SEC on September 23, 2022)
- Amended and Restated Investors Rights Agreement among the Registrant and certain of its stockholders, dated April 20, 2021 (Filed With SEC on September 23, 2022)
- Form of Common Stock Certificate (Filed With SEC on September 23, 2022)
- 2019 Stock Option and Grant Plan, as amended, and forms of award agreements thereunder (Filed With SEC on September 23, 2022)
- Senior Executive Cash Incentive Bonus Plan (Filed With SEC on September 23, 2022)
- Non-Employee Director Compensation Policy (Filed With SEC on September 23, 2022)
- Form of Officer Indemnification Agreement (Filed With SEC on September 23, 2022)
- Form of Director Indemnification Agreement (Filed With SEC on September 23, 2022)
- Amended and Restated Employment Agreement, dated July 7, 2022, between the Registrant and Keith Gottesdiener (Filed With SEC on September 23, 2022)
- Amended and Restated Employment Agreement, dated July 20, 2022, between the Registrant and Jeremy Duffield (Filed With SEC on September 23, 2022)
- Amended and Restated Employment Agreement, dated July 11, 2022, between the Registrant and Ann Lee (Filed With SEC on September 23, 2022)
- Amended and Restated Employment Agreement, dated July 7, 2022, between the Registrant and Carman Alenson (Filed With SEC on September 23, 2022)
- Amended and Restated Employment Agreement, dated July 7, 2022, between the Registrant and Meredith Goldwasser (Filed With SEC on September 23, 2022)
- Collaboration and License Agreement, dated September 26, 2019, between Beam Therapeutics (Filed With SEC on September 23, 2022)
- License Agreement, dated September 26, 2019, between The Broad Institute, Inc. and the Registrant, as amended (Filed With SEC on September 23, 2022)
- Amendment No. 1 to License Agreement, dated May 5, 2020, between The Broad Institute, Inc. and the Registrant (Filed With SEC on September 23, 2022)
- Amendment No. 2 to License Agreement, dated February 18, 2021, between The Broad Institute, Inc. and the Registrant (Filed With SEC on September 23, 2022)
- Pledge from Prime Medicine (Filed With SEC on September 23, 2022)
- License Agreement, dated March 16, 2020, between MIL 21E, LLC and the Registrant, as amended (Filed With SEC on September 23, 2022)
- Consulting Agreement between the Registrant and David Liu, dated September 13, 2019 (Filed With SEC on September 23, 2022)
- Amendment No. 1 to the Consulting Agreement between the Registrant and David Liu, dated October 22, 2021 (Filed With SEC on September 23, 2022)
- Andrew Anzalone Offer Letter, dated December 20, 2019 (Filed With SEC on September 23, 2022)
- Andrew Anzalone Confidentiality, Assignment and Nonsolicitation Agreement, dated October 16, 2020 (Filed With SEC on September 23, 2022)